BTI.H Stock Overview
A development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Bioasis Technologies Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.005 |
| 52 Week High | CA$0.01 |
| 52 Week Low | CA$0.005 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -50.00% |
| 33 Year Change | -98.18% |
| 5 Year Change | -98.08% |
| Change since IPO | -98.89% |
Recent News & Updates
Shareholder Returns
| BTI.H | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 1.0% |
| 1Y | -50.0% | -38.7% | 18.6% |
Return vs Industry: BTI.H underperformed the Canadian Biotechs industry which returned -36.6% over the past year.
Return vs Market: BTI.H underperformed the Canadian Market which returned 10.4% over the past year.
Price Volatility
| BTI.H volatility | |
|---|---|
| BTI.H Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.1% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: BTI.H has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BTI.H's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Deborah Rathjen | www.bioasis.us |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company’s in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007).
Bioasis Technologies Inc. Fundamentals Summary
| BTI.H fundamental statistics | |
|---|---|
| Market cap | CA$397.07k |
| Earnings (TTM) | -CA$2.88m |
| Revenue (TTM) | CA$269.38k |
0.0x
P/S Ratio0.0x
P/E RatioIs BTI.H overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTI.H income statement (TTM) | |
|---|---|
| Revenue | CA$269.38k |
| Cost of Revenue | CA$968.85k |
| Gross Profit | -CA$699.47k |
| Other Expenses | CA$2.18m |
| Earnings | -CA$2.88m |
Last Reported Earnings
Nov 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BTI.H perform over the long term?
See historical performance and comparison